Methods:
In an open-label multicenter trial, patients with pathological stage IB to IIIA NSCLC were randomized into a group receiving paclitaxel (175 mg/m 2 ) plus carboplatin (area under the curve 5) every 3 weeks for four cycles (arm A) or a group receiving orally administered UFT (250 mg/m 2 ) daily for 2 years (arm B). The primary and secondary end points were overall survival and relapse-free survival and toxicity, respectively. There was no significant difference in the 5-year relapsefree survival rate between arms A and B (56% versus 57% [hazard ratio ¼ 0.92, 95% CI: 0.63-1.34, p ¼ 0.50]). Toxicities were well tolerated and there was no treatmentrelated death. Toxicities of any grade or grade 4 were significantly more frequent in the paclitaxel plus carboplatin group (95.7% and 22.1%, respectively) than in the UFT group (76.5% and 1.0%, respectively [p < 0.0001 in both]).
Conclusions:
As adjuvant chemotherapy, paclitaxel plus carboplatin was no better than UFT in terms of survival among patients with stage IB to IIIA NSCLC tumors who underwent complete resection (UMIN000000810).
Introduction
Lung cancer is the most common cause of cancerrelated death worldwide as well as in Japan. Primary surgery is the first-line treatment for patients with limited NSCLC. Even in patients who undergo complete resection, recurrence often impairs clinical outcome. To prevent recurrence due to micrometastases at the time of surgical resection, adjuvant chemotherapies were introduced.
There have been three major trials examining combinations using platinum-based regimens, mainly platinum plus third-generation anticancer agents, which demonstrated a survival benefit in stage II to III disease compared with surgery alone: the International Adjuvant Lung Trial, the National Cancer Institute of Canada Clinical Trials Group JBR10 trial, and the Adjuvant Navelbine International Trialist Association trial. 4 In an exploratory analysis, adjuvant chemotherapy showed a significant survival advantage in a subset of patients with tumors larger than 4 cm in diameter. 4 This suggests that paclitaxel plus carboplatin has a benefit in patients with more progressed stage IB disease rather than as adjuvant chemotherapy in early disease.
In Japan, uracil-tegafur (UFT) alone has been reported to be a beneficial adjuvant strategy for patients with resected NSCLC in stages I to III. 5 On the other hand, usefulness of adjuvant chemotherapy with the combination of platinum and third-generation anticancer agent confirmed by randomized trials has not been reported in Japanese patients. In 2004, when this study had been conducted, a randomized study comparing adjuvant chemotherapy with UFT and an observational study conducted by the Japan Lung Cancer Research Group also indicated that UFT provides a survival advantage compared with surgery alone for patients with stage IB or stage IA NSCLC (tumor size >2 cm). 6 Generally, the combination of platinum and a thirdgeneration anticancer agent is considered to have a stronger anticancer effect than UFT in patients with advanced NSCLC. 7, 8 However, it is unclear whether the platinum plus a third-generation anticancer agent treatment is superior to UFT in adjuvant chemotherapy for completely resected NSCLC.
It is possible that patients who undergo radical surgery are free from cancer cells and are thus already cured without adjuvant therapy. From this point of view, severe adverse effects, especially toxic death due to adjuvant chemotherapy, should be avoided as much as possible. There have been treatment-related deaths in patients treated with cisplatin-based regimens in an adjuvant setting. The incidence of treatment-related deaths in both the International Adjuvant Lung Trial and the JBR10 trial was 0.8, and it was 2.0% in the Adjuvant Navelbine International Trialist Association trial [1] [2] [3] ; however, there were no treatment-related deaths in the CALGB 9633 population treated with paclitaxel plus carboplatin. 4 This is consistent with the results of clinical trials in advanced NSCLC showing that paclitaxel plus carboplatin was less toxic and better tolerated than cisplatin-based regimens in North America. 8, 9 On the basis of these findings, we designed a randomized trial of paclitaxel plus carboplatin and oral UFT in 2004 to evaluate the efficacy and safety of adjuvant chemotherapy in resected stage IB to IIIA NSCLC. 10 Patient enrollment and data collection were performed at each participating institute. The details of the main inclusion and exclusion criteria are listed in Supplementary Tables 1 and 2 .
Patients and Methods

Study Design and Patients
The patients were subsequently randomly assigned to receive either paclitaxel plus carboplatin (arm A) or UFT (arm B) in a 1:1 ratio by using computer-generated random numbers at the Division of Molecular and Clinical Epidemiology, Aichi Cancer Center Research Institute, Aichi, Japan, with the following stratification factors: institution, histologic type (adenocarcinoma versus others), and disease stage (stage IB or II or IIIA) (Fig. 1) . The SLCG 0401 data center, the nonprofit organization Epidemiological and Clinical Research Information Network in Kyoto, Japan, anonymized each participant by assignment of a new number and managed all the study data.
The protocol was approved by the institutional review boards of all the participating institutions. All patients provided written informed consent before enrollment in the trial; consent was obtained from the patients by each investigator at each participating institute.
Treatment and Follow-up
Adjuvant treatment was planned to start within 6 weeks after surgery. In arm A, patients received paclitaxel (175 mg/m 2 ) intravenously over 3 hours followed by a 1-hour infusion of carboplatin (area under the curve Figure 1 . Study design. Flow diagram of the study. Sixteen patients who had agreed to inclusion in this study ultimately refused the protocol treatment before starting therapy and were followed without any adjuvant therapy (13 and 3 in arms A and B, respectively). Two patients who had been randomly assigned to arm B (uracil-tegafur [UFT] administration) were accidentally treated by using the paclitaxel plus carboplatin protocol (arm A). In the end, 386 patients actually received the protocol treatment (188 in arm A and 198 in arm B, with 190 in the paclitaxel plus carboplatin protocol and 196 in the UFT protocol).
[AUC] 5), with each administered on day 1 every 3 weeks for four cycles. In arm B, patients received UFT orally twice or thrice daily every day until 2 years after the start of oral administration; the dose was 300 mg/d when the body surface area was less than 1.40 m 2 , 400 mg/d for a body surface area of 1.40 to 1.80 m 2 , and 500 mg/d for a body surface area greater than 1.80 m 2 . The details of (1) the criteria for discontinuation, entry, or dose modification of protocol treatments and (2) patient evaluations during and after protocol treatments are provided in the Supplementary Method. Further examination (such as by computed tomography scan, magnetic resonance imaging scan, bone scintigraphy, and abdominal ultrasonography) was performed whenever disease relapse, as defined in the Supplementary Method, was considered.
After the protocol treatment had been completed or terminated, no other adjuvant chemotherapy or radiotherapy for primary disease was permitted unless patients had experienced disease relapse.
Outcome
We defined the rate of overall survival (OS) at 5 years as the primary end point and the rate of relapse-free survival (RFS) and toxicity as secondary end points (each definition and evaluation is presented in the Supplementary Method).
We calculated the relative dose intensity (RDI), which was defined as the ratio of planned dose intensity (mg/wk for pclitazxel or carboplatin; mg/d for UFT) to actual dose intensity received for each drug.
Sample Size
We assumed 5-year OS rates of 60 % and 45 % for arms A and B, respectively, on the basis of the previous report.
1 According to these rates, we estimated the required number of patients as 186 patients in each arm (a ¼ 0.05 and b ¼ 0.2). Finally, we set the sample size at 400 after considering the potential dropout of patients on account of ineligibility.
Interim analysis of OS and toxicity is planned to be performed when 200 cases have been enrolled in this study without stopping patient enrollment. The interim analysis of OS did not reach the prespecified p value. In addition, no clear difference in toxicity was seen between the two arms. Therefore, the study was continued as planned (Supplementary Method).
Statistical Analysis
The reference arm of this study was arm A (paclitaxel plus carboplatin). All the survival analyses were conducted on the basis of intention to treat. For the primary end point, OS, we applied a stratified Cox proportional hazard model with institution, histologic type (adenocarcinoma versus others), and disease stage (stage IB or II or IIIA) used as stratifying factors. Other survival analyses used stratified Cox proportional hazard models and stratified log-rank tests with the same stratification factors. Differences in incidence of toxicities between the two arms were evaluated by using Fisher's exact test.
We defined p less than 0.05 as the threshold of statistical significance. All the statistical analyses were executed with STATA software (version14, StataCorp, College Station, TX) and GraphPad Prism 5 (GraphPad Software, La Jolla, CA). Figure 1 . The baseline characteristics of the patients are summarized in Table 1 .
Results
Patient Characteristics
A total of 402 patients were enrolled in this trial from 40 institutions (Supplementary Table 3) in Japan between November 2004 and November 2010 because the expected number of participants was achieved. The details of patient distribution are shown in
Delivery of Chemotherapy
Details of delivery of the chemotherapies are provided in Supplementary Tables 4 and 5 . As for the paclitaxel plus carboplatin protocol (n ¼ 190), 163 patients (85.8%) received all four cycles of chemotherapy. During the whole treatment course, 25 patients (13.2%) needed dose reduction and 22 patients (11.6%) The median RDIs of paclitaxel, carboplatin, and UFT were 92.6 % (0.4-102.4), 92.7 % (0.0-106.8), and 87.7 % (2.7-116.0), respectively. Because the whole treatment period of UFT was 2 years, 51 patients (25.3%) experienced relapse of disease (n ¼ 49) or a second malignancy in another organ (n ¼ 2) and stopped the protocol treatment (see Supplementary Table 5 ). On the other hand, only four patients (2.1%) experienced relapse of disease, and none of the patients experienced a second malignancy during protocol treatment (treatment period of approximately 3 months) in arm A (see Supplementary Table 4 ).
Toxicity
A summary of the adverse events is shown in Table 2 . The patients who suffered from toxicity of any grade were significantly more frequent in the paclitaxel plus carboplatin group (n ¼ 180 [95.7%]) than in the UFT group (n ¼ 150 [76.5%] (p < 0.0001).
The main adverse events in the paclitaxel plus carboplatin group were hematological toxicities, neuropathy, alopecia, and gastrointestinal toxicities, the frequencies of which at any grade of toxicity were more than 30%. On the other hand, there were no adverse events with more than 30% frequency in the UFT group; increased aspartate transaminase, alanine transaminase, lactate dehydrogenase, and total bilirubin level; anemia; and anorexia were the main adverse events in the UFT group, with less than 30% frequency. Severe adverse events of leukopenia and neutropenia (grades 3 or 4) were significantly more frequent in the paclitaxel plus carboplatin group than in the UFT group (42.1% versus 0.5% and 17.4% versus 0%, respectively [p < 0.0001 in each]) ( Table 2 ). Grade 4 toxicities of any kind were also significantly more frequent in the paclitaxel plus carboplatin group (n ¼ 42 [22.1%]) than in the UFT group (n ¼ 2 [1.0%]) (p < 0.0001). There were no treatmentrelated deaths during the protocol treatment.
As two patients in arm B accidentally received paclitaxel plus carboplatin, we also evaluated the toxicities of arms A (n ¼ 188) and B (n ¼ 198) and found no significant difference in the incidence of toxicities between those in the paclitaxel plus carboplatin group (n ¼ 190) and those in the UFT group (n ¼ 196).
Survival
Survival analyses were performed on the basis of intention to treat. The median follow-up period of all 402 cases was 5.8 years (0. 16-11.23 ) and the median follow-up period for survivors (n ¼ 252) was 6. (Fig. 2B) .
As for pathological stage, the edition of Union for International Cancer Control TNM staging system had been updated from the sixth edition to the seventh edition 11 during the study period (in 2009). Because pathological stage is one of the stratification factors in this study, we also evaluated the impact of the three types of revised pathological stage (Supplementary Table 6 ) on clinical outcome and found that OS and RFS rates showed no significant difference between these three classifications (data not shown).
Discussion
When SLCG0401 was under design in early 2004, the evidence of adjuvant chemotherapy for stage I to IIIA NSCLC was limited. The results of two prospective trials of UFT had been published to show survival benefit of treatment in stage IB adenocarcinoma 6 and stage I to III NSCLC. 5 The number of cases in the former trial is limited. Regarding paclitaxel plus carboplatin, we chose this regimen expecting its superiority to UFT on the basis of the preliminary report for stage IB disease that was presented in 2004 as the latest topic. However, the final report on the paclitaxel plus carboplatin regimen, which was published in 2008, did not demonstrate an advantage as adjuvant therapy in stage IB disease. 4 In our study, 228 out of 402 patients (54.3%) were in stage IB, and there were no significant differences in OS and RFS rates between the two groups in the patients with stage IB disease.
In our study, paclitaxel plus carboplatin did not improve survival compared with UFT among patients with completely resected stage IB to IIIA NSCLC. Generally, treatment with platinum plus third-generation antitumor agents is considered to have a strong antitumor effect compared with other regimens, such as cisplatin with second-generation agents or monotherapy with any cytotoxic agent. 8, 9, 12, 13 UFT is generally considered a mild antitumor agent in NSCLC.
Among the platinum-based regimens, vinorelbine plus cisplatin was demonstrated to be associated with favorable prognosis in stage II to III NSCLC compared with surgery alone. 2, 3 However, subset analysis did not demonstrate any benefit in stage IB disease.
2,3 Although G2  G3  G4  G1  G2  G3  G4   Anemia  64  38  2  1  42  5  0  0  Leukopenia  18  78  31  2  18  8  0  0  Neutropenia  8  13  42  38  7 paclitaxel plus carboplatin did not show a survival advantage in all patients with stage IB disease as a whole compared with surgery alone, it did show a survival benefit in stage IB patients with tumors larger than 4 cm in diameter. 4 These data suggest that agents with strong antitumor effects might be suitable for resected NSCLC in a more advanced stage than for early-stage NSCLC. On the other hand, a recent randomized phase II study showed that monotherapy with S-1, a modified oral agent of UFT, for 1 year was preferable to S-1 plus cisplatin for four cycles in resected stage II to IIIA NSCLC, indicating similar RFS and OS with less toxicity. 14 Of note, a recent phase III trial demonstrated that S-1 plus cisplatin was not inferior to docetaxel plus cisplatin in patients with advanced NSCLC, 15 suggesting that the efficacy of S-1 plus cisplatin is similar to that of platinum plus a third-generation anticancer agent. These results imply that adjuvant therapy with S-1 monotherapy for 1 year may have efficacy similar to that of platinum plus a third-generation anticancer agent for resected NSCLC. Thus, although it may be a necessary feature in the case of fluorouracil, long-term treatment might also be an important factor for favorable prognosis in patients with completely resected NSCLC.
We selected the doses of 175 mg/m 2 for paclitaxel and AUC 5 for carboplatin. These doses are lower than those of the standard regimen. We chose these doses to avoid severe toxicity and to improve patient compliance with the treatment regimen after radical surgery. Although chemotherapy with 225 mg/m 2 of paclitaxel and carboplatin, AUC 6, has been reported by a dose escalation study 16 to be tolerated in Japanese patients with advanced NSCLC, grade 3 or 4 neutropenia was observed in 75% to 88% of patients in two Japanese phase III studies for untreated NSCLC with doses of 200 mg/m 2 for paclitaxel and AUC 6 for carboplatin. 17, 18 One treatment-related death occurred in each study (one of 148 [0.7%] and one of 279 [0.4%]). 17, 18 In phase III trials for advanced NSCLC conducted in North America with paclitaxel, 225 mg/m 2 , and carboplatin, AUC 6, grade 3 or 4 neutropenia was observed in about 60% of patients. 8, 9 In the CALGB 9633 study, which was also conducted in North America, adjuvant chemotherapy for patients with resected NSCLC was performed with 200 mg/m 2 of paclitaxel and carboplatin AUC 6, and 35% of patients suffered from grade 3 or 4 neutropenia, which was similar to what we observed (42.1%). These results suggest that the tolerability of paclitaxel and carboplatin differs by ethnicity and that Japanese patients experience more toxicity in response to paclitaxel and carboplatin. Thus, we believe that our dose setting is appropriate as adjuvant therapy for Japanese patients with resected NSCLC with regard to toxicity. The toxicity profile of UFT was similar to that in previous reports; 5, 6 although the rate of toxicity was higher in our study, it is still well tolerated.
Quality of life is an important consideration in the clinical trials related to adjuvant chemotherapy. However, quality of life has not been investigated in this study. As for RDIs, these values were only advisories based on limited information because we had not planned to calculate RDI in this study. These were limitations of this study.
In conclusion, four cycles of paclitaxel plus carboplatin were not better than UFT monotherapy in terms of survival among Japanese patients with resected stage IB to IIIA NSCLC. Although both treatments are feasible, toxicity was milder with UFT than with paclitaxel plus carboplatin. 
